home

C-Myc oncogene determines function of immune cells

R&Dfiercebiotech2016-04-14 09:07 Read   90

Asymmetric cell division plays an important role during the development of our nervous and digestive systems. It is thought that T cells, a type of immune cell, can also divide asymmetrically, giving rise to two different daughter cells.

Arena’s cannabinoid pain drug passes early-stage test

R&Dyahoo2016-04-13 13:04 Read   88

Arena Pharmaceuticals, Inc. (ARNA) today announced favorable results from its Phase 1b multiple-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor with potential utility in the treatment of pain.

First Zika vaccine may start clinical trials in September; Congress yet to fund research

R&Dhealthcarefinancenews2016-04-13 10:56 Read   96

Without funding, feds may have to redirect money currently dedicated for research into malaria, tuberculosis and a universal flu vaccine.

Elanco Gets FDA Nod on Biological Drug for Dairy Cows

R&Dxconomy2016-04-13 09:16 Read   89

A mastitis diagnosis in a cow spells trouble for a dairy farmer, who faces certain loss in milk production and possible loss of the cow. Antibiotics can treat this infection of the udder, but these drugs have fallen out of favor due to growing drug resistance.

Big year at Amgen delivers $2M pay hike for CEO Bradway, to $16M

R&Dfiercepharma2016-04-12 13:18 Read   88

Amgen ($AMGN) had a big year in 2015, as its newly filed proxy statement takes pains to emphasize. Revenue grew to $21.7 billion, an 8% hike.

Diagnostic tool reliably predicted obstructive sleep apnea

R&Dhealio2016-04-12 10:56 Read   98

Researchers have validated the use of the Sleep Apnea Clinical Score, according to data published in Mayo Clinic Proceedings.

Lilly CEO Lechleiter nabs $16.6M in 2015 pay, with hefty boosts to incentive compensation

R&Dfiercepharma2016-04-11 12:58 Read   94

Eli Lilly CEO John Lechleiter has suffered some tough years this decade, as top sellers such as Zyprexa went off patent and a series of R&D setbacks put a crimp in the company's plans to fill those gaps. But 2015 turned out better than expected--and it shows in Lechleiter's pay.

J&J grabs prostate cancer rights for Tesaro's niraparib in $500M deal

R&DFiercebiotech2016-04-07 13:04 Read   87

Oncology powerhouse J&J ($JNJ) has stepped up with a $500 million deal to nab the commercial rights to Tesaro's ($TSRO) late-stage cancer drug niraparib, specifically carving out ownership of the drug for its growing prostate cancer franchise.

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders

R&DPR newswire2016-04-07 11:27 Read   112

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited and Heptares have entered into a definitive agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer's disease.

Valeant moves quickly to slash jobs, beginning with Addyi, dermatology sales reps

R&Dfircepharma2016-04-06 13:01 Read   125

Last month, when outlining dismal sales performances in several of Valeant's ($VRX) key businesses, CEO J. Michael Pearson promised a restructuring.

Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases

R&DBusinesswire2016-04-05 08:59 Read   622

Given the company’s long-standing commitment to and expertise in liver disease, we are confident that Gilead is the ideal partner to accelerate and maximize the potential of the ACC inhibitor program” Tweet this

Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

R&DFirstword2016-04-01 11:19 Read   88

Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from the first paroxysmal nocturnal hemoglobinuria (PNH) patient treated with subcutaneously administered Coversin.